Hematologic Cancers

Triplet Maintenance After HSCT Improves PFS vs Lenalidomide Alone in Multiple Myeloma

By

Jonathan Goodman, MPhil

Publish Date June 30, 2022

Results of the phase 3 ATLAS trial revealed a potential new standard of care, according to researchers.

High-Dose Methotrexate and Nephrotoxicity Risk in Patients With Hematologic Cancers

By

Jennifer Larson

Publish Date June 28, 2022

The retrospective analysis included 144 patients in three Australian health care facilities with a total of 539 episodes of high-dose methotrexate.

Orelabrutinib-Sintilimab Yields Responses in Primary CNS Lymphoma

By

Jen Smith

Publish Date June 28, 2022

The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.

Guidelines for CML Not Followed in the Real World

By

John Schieszer

Publish Date June 28, 2022

“Excellent” overall survival is achievable with currently available drugs, according to researchers.

Study Examines Association Between Undifferentiated Pruritus and Hematologic Cancers

By

Jennifer Larson

Publish Date June 27, 2022

The careful consideration of cancer risk is especially important during the first year after the presentation of pruritus.